Oblong oval tablets, white coated, 750 mg. On the cross section, two layers are visible - the outer one is white, the inner one is white with a yellowish or brownish tint.
60 tablets in a plastic bottle with a snap-on lid, together with instructions for use, are placed in a cardboard box.
DONA has anti-inflammatory and analgesic effects, makes up for endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans and hyaluronic acid in synovial fluid; increases the permeability of the joint capsule, restores the enzymatic processes in the cells of the synovial membrane and articular cartilage. It promotes the fixation of sulfur during the synthesis of chondroitin sulfuric acid, facilitates the normal deposition of calcium in bone tissue, inhibits the development of degenerative processes in the joints, restores their function, reducing joint pain.
Absorption in the gastrointestinal tract 90%, bioavailability 25%, elimination half-life - 70 hours.
Osteoarthrosis of the peripheral joints and spine, osteochondrosis.
Individual hypersensitivity to the active substance and other components of the drug, severe chronic renal failure. It is not recommended to prescribe the drug during pregnancy and lactation, as well as in childhood (up to 12 years) due to the lack of scientific clinical data in this category of patients.
Pregnancy and lactation
The appointment of the drug during pregnancy and lactation is not recommended due to the lack of scientific clinical data in this category of patients.
When using the drug in patients with impaired glucose tolerance, with severe hepatic and renal failure, medical supervision is necessary.
One tablet contains: active substance: glucosamine sulfate sodium chloride 942 mg (equivalent to glucosamine sulfate 750 mg and sodium chloride 192 mg); excipients: microcrystalline cellulose 68 mg, povidone K 25 (polyvinylpyrrolidone K 25) 45 mg, croscarmellose sodium 20 mg, macrogol 6000 (polyethylene glycol 6000) 15 mg, magnesium stearate 8.50 mg, talc 1.50 mg; shell: methacrylic acid and methyl methacrylate copolymer [1: 1] (Eudragit L 12.5) 1.0 mg, ground titanium dioxide 11.50 mg, talc 10.55 mg, methyl methacrylate, trimethylammonioethyl methacrylate chloride and ethyl acrylate copolymer [2: 0.2: 1] (Eudragit RL 30 D) 4.50 mg, triacetin (glycerol triacetate) 0.90 mg, macrogol 6000 (polyethylene glycol 6000) 0.55 mg.
Dosage and administration
1 tablet of 750 mg is taken orally 2 times a day, preferably with meals, with a glass of water. Symptomatic effect occurs 2-3 weeks after the use of the drug. The minimum course of therapy is 4-6 weeks.
If necessary, the treatment is repeated with an interval of 2 months. The duration and treatment regimen is prescribed by the attending physician.
Precautions for use:
Caution should be exercised in patients with allergies to seafood (shrimp, shellfish). The drug contains 75.5 mg of sodium per tablet, which should be considered in patients who follow a controlled sodium diet. Use with caution in bronchial asthma and diabetes.
The drug is well tolerated, in some cases, possible: gastralgia, flatulence, nausea, diarrhea, constipation; headache, drowsiness; allergic reactions - erythema, urticaria, itching.
Compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids. Increases the absorption of tetracyclines, reduces - semisynthetic penicillins, chloramphenicol; enhances the effect of coumarin anticoagulants.
Cases of overdose are unknown. Treatment: gastric lavage, symptomatic therapy.
Store at a temperature not exceeding 25 ºC. Keep out of the reach of children.
3 years. Do not use after the expiration date indicated on the package.